Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells

Peng Wang, Jing Zhang, Anita Bellail, Wen Jiang, Judith Hugh, Norman M. Kneteman, Chunhai Hao

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has recently emerged as a cancer therapeutic agent because it is capable of preferentially inducing apoptosis in human cancer over normal cells. The majority of human pancreatic cancers, unfortunately, are resistant to TRAIL treatment. Here, we show that the inhibition of caspase-8 cleavage is the most upstream event in TRAIL resistance in pancreatic cancers. TRAIL treatment led to the cleavage of caspase-8 and downstream caspase-9, caspase-3, and DNA fragmentation factor 45 (DFF45) in TRAIL-sensitive pancreatic cancer cell lines (BXPC-3, PACA-2). This caspase-8-initiated caspase cascade, however, was inhibited in TRAIL-resistant pancreatic cancer cell lines (PANC-1, ASPC-1, CAPAN-1, CAPAN-2). The long and short forms of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIPL, c-FLIPS) were highly expressed in the TRAIL-resistant as compared to the sensitive cells; knockdown of c-FLIPL and c-FLIPS by a short hairpin RNA (shRNA) rendered the resistant cells sensitive to TRAIL-induced apoptosis through the cleavage of caspase-8 and activation of the mitochondrial pathway. Receptor-interacting protein (RIP) has been reported in TRAIL-induced activation of NF-κB and we show here that knockdown of RIP sensitized the resistant cells to TRAIL-induced apoptosis. These results indicate the role of c-FLIP and RIP in caspase-8 inhibition and thus TRAIL resistance. Treatment of the resistant cells with camptothecin, celecoxib and cisplatin resulted in the downregulation of c-FLIP and caused a synergistic apoptotic effect with TRAIL. These studies therefore suggest that combination treatment with chemotherapy can overcome TRAIL resistance and enhance TRAIL therapeutic efficacy in treating pancreatic cancers.

Original languageEnglish (US)
Pages (from-to)2237-2246
Number of pages10
JournalCellular Signalling
Volume19
Issue number11
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Receptor-Interacting Protein Serine-Threonine Kinases
Pancreatic Neoplasms
Caspase 8
Apoptosis
Celecoxib
Therapeutics
Cell Line
Caspase 1
Camptothecin
Caspase 9
Caspases
Caspase 3
Small Interfering RNA
Cisplatin
Neoplasms
Down-Regulation
Tumor Necrosis Factor-alpha
Ligands
Drug Therapy

Keywords

  • Apoptosis
  • c-FLIP
  • Chemotherapy
  • Pancreatic cancer
  • RIP
  • TRAIL

ASJC Scopus subject areas

  • Cell Biology

Cite this

Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. / Wang, Peng; Zhang, Jing; Bellail, Anita; Jiang, Wen; Hugh, Judith; Kneteman, Norman M.; Hao, Chunhai.

In: Cellular Signalling, Vol. 19, No. 11, 01.11.2007, p. 2237-2246.

Research output: Contribution to journalArticle

Wang, Peng ; Zhang, Jing ; Bellail, Anita ; Jiang, Wen ; Hugh, Judith ; Kneteman, Norman M. ; Hao, Chunhai. / Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. In: Cellular Signalling. 2007 ; Vol. 19, No. 11. pp. 2237-2246.
@article{35cb361806714c87805740b1a8d0a273,
title = "Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells",
abstract = "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has recently emerged as a cancer therapeutic agent because it is capable of preferentially inducing apoptosis in human cancer over normal cells. The majority of human pancreatic cancers, unfortunately, are resistant to TRAIL treatment. Here, we show that the inhibition of caspase-8 cleavage is the most upstream event in TRAIL resistance in pancreatic cancers. TRAIL treatment led to the cleavage of caspase-8 and downstream caspase-9, caspase-3, and DNA fragmentation factor 45 (DFF45) in TRAIL-sensitive pancreatic cancer cell lines (BXPC-3, PACA-2). This caspase-8-initiated caspase cascade, however, was inhibited in TRAIL-resistant pancreatic cancer cell lines (PANC-1, ASPC-1, CAPAN-1, CAPAN-2). The long and short forms of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIPL, c-FLIPS) were highly expressed in the TRAIL-resistant as compared to the sensitive cells; knockdown of c-FLIPL and c-FLIPS by a short hairpin RNA (shRNA) rendered the resistant cells sensitive to TRAIL-induced apoptosis through the cleavage of caspase-8 and activation of the mitochondrial pathway. Receptor-interacting protein (RIP) has been reported in TRAIL-induced activation of NF-κB and we show here that knockdown of RIP sensitized the resistant cells to TRAIL-induced apoptosis. These results indicate the role of c-FLIP and RIP in caspase-8 inhibition and thus TRAIL resistance. Treatment of the resistant cells with camptothecin, celecoxib and cisplatin resulted in the downregulation of c-FLIP and caused a synergistic apoptotic effect with TRAIL. These studies therefore suggest that combination treatment with chemotherapy can overcome TRAIL resistance and enhance TRAIL therapeutic efficacy in treating pancreatic cancers.",
keywords = "Apoptosis, c-FLIP, Chemotherapy, Pancreatic cancer, RIP, TRAIL",
author = "Peng Wang and Jing Zhang and Anita Bellail and Wen Jiang and Judith Hugh and Kneteman, {Norman M.} and Chunhai Hao",
year = "2007",
month = "11",
day = "1",
doi = "10.1016/j.cellsig.2007.06.001",
language = "English (US)",
volume = "19",
pages = "2237--2246",
journal = "Cellular Signalling",
issn = "0898-6568",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells

AU - Wang, Peng

AU - Zhang, Jing

AU - Bellail, Anita

AU - Jiang, Wen

AU - Hugh, Judith

AU - Kneteman, Norman M.

AU - Hao, Chunhai

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has recently emerged as a cancer therapeutic agent because it is capable of preferentially inducing apoptosis in human cancer over normal cells. The majority of human pancreatic cancers, unfortunately, are resistant to TRAIL treatment. Here, we show that the inhibition of caspase-8 cleavage is the most upstream event in TRAIL resistance in pancreatic cancers. TRAIL treatment led to the cleavage of caspase-8 and downstream caspase-9, caspase-3, and DNA fragmentation factor 45 (DFF45) in TRAIL-sensitive pancreatic cancer cell lines (BXPC-3, PACA-2). This caspase-8-initiated caspase cascade, however, was inhibited in TRAIL-resistant pancreatic cancer cell lines (PANC-1, ASPC-1, CAPAN-1, CAPAN-2). The long and short forms of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIPL, c-FLIPS) were highly expressed in the TRAIL-resistant as compared to the sensitive cells; knockdown of c-FLIPL and c-FLIPS by a short hairpin RNA (shRNA) rendered the resistant cells sensitive to TRAIL-induced apoptosis through the cleavage of caspase-8 and activation of the mitochondrial pathway. Receptor-interacting protein (RIP) has been reported in TRAIL-induced activation of NF-κB and we show here that knockdown of RIP sensitized the resistant cells to TRAIL-induced apoptosis. These results indicate the role of c-FLIP and RIP in caspase-8 inhibition and thus TRAIL resistance. Treatment of the resistant cells with camptothecin, celecoxib and cisplatin resulted in the downregulation of c-FLIP and caused a synergistic apoptotic effect with TRAIL. These studies therefore suggest that combination treatment with chemotherapy can overcome TRAIL resistance and enhance TRAIL therapeutic efficacy in treating pancreatic cancers.

AB - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has recently emerged as a cancer therapeutic agent because it is capable of preferentially inducing apoptosis in human cancer over normal cells. The majority of human pancreatic cancers, unfortunately, are resistant to TRAIL treatment. Here, we show that the inhibition of caspase-8 cleavage is the most upstream event in TRAIL resistance in pancreatic cancers. TRAIL treatment led to the cleavage of caspase-8 and downstream caspase-9, caspase-3, and DNA fragmentation factor 45 (DFF45) in TRAIL-sensitive pancreatic cancer cell lines (BXPC-3, PACA-2). This caspase-8-initiated caspase cascade, however, was inhibited in TRAIL-resistant pancreatic cancer cell lines (PANC-1, ASPC-1, CAPAN-1, CAPAN-2). The long and short forms of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIPL, c-FLIPS) were highly expressed in the TRAIL-resistant as compared to the sensitive cells; knockdown of c-FLIPL and c-FLIPS by a short hairpin RNA (shRNA) rendered the resistant cells sensitive to TRAIL-induced apoptosis through the cleavage of caspase-8 and activation of the mitochondrial pathway. Receptor-interacting protein (RIP) has been reported in TRAIL-induced activation of NF-κB and we show here that knockdown of RIP sensitized the resistant cells to TRAIL-induced apoptosis. These results indicate the role of c-FLIP and RIP in caspase-8 inhibition and thus TRAIL resistance. Treatment of the resistant cells with camptothecin, celecoxib and cisplatin resulted in the downregulation of c-FLIP and caused a synergistic apoptotic effect with TRAIL. These studies therefore suggest that combination treatment with chemotherapy can overcome TRAIL resistance and enhance TRAIL therapeutic efficacy in treating pancreatic cancers.

KW - Apoptosis

KW - c-FLIP

KW - Chemotherapy

KW - Pancreatic cancer

KW - RIP

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=34548410333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548410333&partnerID=8YFLogxK

U2 - 10.1016/j.cellsig.2007.06.001

DO - 10.1016/j.cellsig.2007.06.001

M3 - Article

C2 - 17693058

AN - SCOPUS:34548410333

VL - 19

SP - 2237

EP - 2246

JO - Cellular Signalling

JF - Cellular Signalling

SN - 0898-6568

IS - 11

ER -